Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Receivables (2016 - 2026)

Bio-Techne has reported Receivables over the past 16 years, most recently at $184.6 million for Q4 2025.

  • For Q4 2025, Receivables fell 15.29% year-over-year to $184.6 million; the TTM value through Dec 2025 reached $184.6 million, down 15.29%, while the annual FY2025 figure was $206.9 million, 14.3% down from the prior year.
  • Receivables for Q4 2025 was $184.6 million at Bio-Techne, roughly flat from $183.9 million in the prior quarter.
  • Over five years, Receivables peaked at $241.4 million in Q2 2024 and troughed at $145.4 million in Q2 2021.
  • A 5-year average of $196.5 million and a median of $203.3 million in 2022 define the central range for Receivables.
  • Biggest five-year swings in Receivables: soared 34.34% in 2021 and later dropped 17.79% in 2025.
  • Year by year, Receivables stood at $152.9 million in 2021, then rose by 20.84% to $184.8 million in 2022, then rose by 12.28% to $207.5 million in 2023, then increased by 5.06% to $217.9 million in 2024, then fell by 15.29% to $184.6 million in 2025.
  • Business Quant data shows Receivables for TECH at $184.6 million in Q4 2025, $183.9 million in Q3 2025, and $206.9 million in Q2 2025.